IoM seeks to augment Enzi/Kennedy bill
The Institute of Medicine's Committee on the Assessment of the U.S. Drug Safety System seeks to work with Sens. Michael Enzi (R-Wyo.) and Edward Kennedy (D-Mass.) on their "Enhancing Drug Safety & Innovation Act." "We certainly hope that when they start negotiations over that bill that the chair of our committee can go and testify in Congress and the bill can incorporate more of what is in the committee report," IoM Committee Study Director Kathleen Stratton said at the Academy of Managed Care Pharmacy Educational Conference Oct. 6. The committee's report, released in September, calls for sweeping changes at FDA (1The Pink Sheet" Oct. 2, 2006, p. 5)...
You may also be interested in...
A separate postmarketing safety center may become necessary if the recommendations made by the Institute of Medicine's Committee on the Assessment of the U.S. Drug Safety System do not result in sufficient reforms of FDA's safety oversight, the committee says
In the second part of Generics Bulletin’s exclusive interview with Fresenius Kabi’s senior vice president for biosimilars in the US, Ali Ahmed, he explains why Kabi is relishing the prospect of competing in pegfilgrastim and what the acquisition of mAbxience means for the company’s prospects and vision.
The pharmaceutical industry and the UK government are beginning a series of round table discussions on the shape of the future voluntary drug pricing and access scheme (VPAS), ahead of the formal negotiations that are scheduled to start in April.